Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $40.80 | Total: $204.00 |
| 1 | 10 | $34.56 | Total: $345.60 |
| 1 | 25 | $29.28 | Total: $732.00 |
| 1 | 50 | $24.96 | Total: $1,248.00 |
| 1 | 100 | $21.60 | Total: $2,160.00 |
Overview
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
Chemical Properties
| Molecular Formula | C20H12F2N6 |
| Molecular Weight | 374.35 |
| CAS Numbers | 943540-74-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models [abstract]. In Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia [PA] AACR; Cancer Res 2018;78[13 Suppl] Abstract nr 4791.